Traws Pharma (TRAW) Tops Q2 EPS by 27c

Traws Pharma (NASDAQ: TRAW) reported Q2 EPS of ($0.16), $0.27 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Traws Pharma (TRAW) click here.

You May Also Be Interested In

• JPMorgan Upgrades Graphic Packaging Holding Company (GPK) to Overweight
• Raymond James Downgrades Accelerant Holdings (ARX) to Underperform
• Jefferies Starts China Oilfield Services (A-Shares) (601808:CH) at Buy